Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

Narcolepsy type 1 is a chronic, rare neurological disease caused by the loss of orexin neurons in the brain. Orexin is a ...

In a small study, patients who have successfully lost weight with weekly GLP-1 treatment maintain their weight loss and ...

As of September 30, 2025, Corvus had cash, cash equivalents and marketable securities of $65.7 million as compared to $52.0 million as of December 31, 2024. Consistent with last quarter, Corvus ...

A once-daily oral quadruple receptor agonist induced up to 13.8% weight loss at 13 weeks among adults with overweight or ...

Walmart is joining Costco, Sam’s Club, and CVS in offering cheaper prices for customers paying out of pocket for Zepbound, Ozempic, or Wegovy.

Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with comorbid COPD.

Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...

The Food and Drug Administration (FDA) just announced that over 580,000 bottles of blood pressure medications made by Teva ...

In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...